Cargando…
A same‐day assay predicts apoptotic response to combined BCL‐2 and MCL‐1 BH3‐mimetic targeting in multiple myeloma cells
Recent advances in treatment options for multiple myeloma (MM) have positive impact on patient survival. However, there is a short fall of rapid and reliable assays that can predict patient response to novel agents. The anti‐apoptotic proteins B‐cell lymphoma‐2 (BCL‐2) and myeloid cell leukaemia‐1 (...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175957/ https://www.ncbi.nlm.nih.gov/pubmed/35846088 http://dx.doi.org/10.1002/jha2.133 |